NCT06857240View on ClinicalTrials.gov

Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis

PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Dermatomyositis
Interventions
DRUG

Ruxolitinib Topical Cream

1.5% cream

Trial Locations (1)

44195

RECRUITING

Cleveland Clinic, Cleveland

All Listed Sponsors
lead

The Cleveland Clinic

OTHER